2025年，公司坚持"国内国外双轮驱动"的基本战略，稳步构建新的业务增长基本盘。在聚焦主业的基础 上积极布局功能性敷料、卫生护理产品，持续推动功能性敷料、卫生护理等产品的销售。同时，公司海 外业务有效抵御了国际贸易冲突的影响，坚持布局新市场新渠道，实现了营业收入的进一步增长。 格隆汇1月30日丨奥美医疗(002950.SZ)公布，预计2025年归属于上市公司股东的净利润21,550.31万元— 25,750.21万元，比上年同期下降30.16%—41.55%，归属于上市公司股东的扣除非经常性损益的净利润 17,950.31万元—22,150.21万元，比上年同期下降35.49%—47.72%。 ...

Group 1 - The core viewpoint of the news highlights the current financial performance and market position of Aomei Medical, indicating a low PE ratio compared to the industry average [1][3] - As of July 24, Aomei Medical's stock closed at 9.2 yuan, with a PE ratio of 16.13, marking a 76-day low, and a total market capitalization of 5.826 billion yuan [1] - The medical device industry has an average PE ratio of 54.55, with Aomei Medical ranking 34th among its peers [1] Group 2 - Aomei Medical specializes in the research, production, and sales of medical consumables, disposable medical devices, infection protection products, and home care products [2] - The company has received multiple accolades, including being listed among the top 100 private manufacturing enterprises in Hubei and recognized for its intelligent manufacturing projects [2] - In the first quarter of 2025, Aomei Medical reported a revenue of 759 million yuan, a year-on-year increase of 1.64%, while net profit decreased by 7.86% to 86.5 million yuan [3]